Synergy Pharmaceuticals (FRA:S90) FCF Margin % : -140.39% (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Synergy Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2018 was €-13.36 Mil. Synergy Pharmaceuticals's Revenue for the three months ended in Sep. 2018 was €9.52 Mil. Therefore, Synergy Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2018 was -140.39%.

As of today, Synergy Pharmaceuticals's current FCF Yield % is -5,300.04%.

The historical rank and industry rank for Synergy Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:S90' s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: -294.18

FRA:S90's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: -0.67 vs FRA:S90: -294.18

Synergy Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Synergy Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals FCF Margin % Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

FCF Margin %

Get a 7-Day Free Trial

-1,266.92

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
FCF Margin %	Get a 7-Day Free Trial															-1,184.29	-351.05	-417.64	-308.68	-140.39

Competitive Comparison of Synergy Pharmaceuticals's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synergy Pharmaceuticals's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's FCF Margin % falls into.

Synergy Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Synergy Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2017 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2017 )	/	Revenue (A: Dec. 2017 )
	=	-180.068	/	14.213
	=	-1,266.92 %

Synergy Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2018 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2018 )	/	Revenue (Q: Sep. 2018 )
	=	-13.361	/	9.517
	=	-140.39 %

Synergy Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines